10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today several changes to its executive team.

10x Genomics Announces Senior Leadership Changes

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024.

10x Genomics Reports Second Quarter 2024 Financial Results

Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics

Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People PLEASANTON, Calif. , Aug. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today its involvement in TenK10K, a large-scale, multi-year study led by the Garvan Institute of Medical Research.

10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

The consensus price target hints at an 85.7% upside potential for 10x Genomics (TXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does 10x Genomics (TXG) Have the Potential to Rally 85.65% as Wall Street Analysts Expect?

10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?

PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024.

10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.

What's Going On With 10x Genomics Stock On Wednesday?

Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire/ -- 10x Genomics, Inc.  (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate.

New Insights Into Cleft Palate Unlocked With 10x Genomics' Single Cell and Spatial Technologies

10x Genomics has experienced a significant decline in share price, currently trading around $20 per share, with no bullish indicators for a potential reversal. Recent performance shows growth in total revenue to $141M, but with a decrease in consumables revenue and a rise in operating costs, leading to an operating loss. Factors contributing to the decline in TXG include economic influences, fading growth prospects, supply chain issues, legal battles with NanoString Technologies, and a lack of retail investor interest.

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel.

10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating 10x Genomics, Inc. (NASDAQ:TXG) on behalf of the company's stockholders. The investigation seeks to determine whether 10x Genomics and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of 10x Genomics, Inc. (NASDAQ: TXG) and Encourages Investors to Contact the Firm

New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , May 29, 2024 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel.

10x Genomics Launches 5,000-Plex Gene Panel for Xenium

Akoya Biosciences Inc

Bionano Genomics

Cytek Biosciences

Danaher

Standard BioTools Inc

908 Devices

Olink Holding AB

Singular Genomics Systems

QIAGEN

Quantum-Si

Revvity Inc

Seer

Thermo Fisher Scientific

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University. The U.S. District Court recently ruled in Vizgen's favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation. The Court's ruling substantially strengthens Vizgen's position aga.

Vizgen Announces Significant Win in Ongoing Patent Litigation Against 10x Genomics and Harvard University

Tesla

Betting big on the future is not easy. Investing guru Cathie Wood attempts to discern the big ideas that will shape tomorrow and acts on them by buying large tranches of stock for her Ark Invest family of exchange-traded funds (ETFs).

Cathie Wood's Latest Buys: 3 Stocks the ARK Invest CEO Can't Get Enough Of

Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

International Markets and 10x Genomics (TXG): A Deep Dive for Investors

PLEASANTON, Calif. , May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m.

10x Genomics to Present at the BofA Securities 2024 Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made. The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ: TXG). The UPC has also ordered Curio Bioscience not to offer any product that would violate claim 14 of the ‘391 patent in France, Germany, and.

Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Cassie Corneau - Director of Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens, Inc. Patrick Donnelly - Citigroup Daniel Arias - Stifel Financial Doug Schenkel - Wolfe Research Dan Brennan - TD Cowen Matt Larew - William Blair Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Partners Michael Ryskin - Bank of America Tejas Savant - Morgan Stanley Luke Sergott - Barclays Kyle Mikson - Canaccord Genuity Operator Good day everyone and welcome to the 10x Genomics First Quarter 2024 Earnings Call. Today's call is being recorded.

10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

PLEASANTON, Calif. , April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024.

10x Genomics Reports First Quarter 2024 Financial Results

Cardinal Health

Hologic

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

3 Medical Products Stocks Set to Beat This Earnings Season

10x Genomics (TXG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

News for 10X Genomics Stock (TXG)